ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

betamethasone dipropionate

Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.

Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.

Drug pageBetamethasone dipropionate: every studyMany companies study it; this page follows only the 26 they lead. All 42 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 3, 200526 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharma180 open or runningphase 4since Nov 3, 2005Sep 15, 2005none ahead
MC2 Therapeuticsits history only50 open or runningphase 3since Oct 9, 2017Oct 9, 2017none ahead
Glenmark Pharmaceuticals Ltd. Indiaits history only10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
Huadong Medicineits history only10 open or runningphase 3since Dec 11, 2025Dec 11, 2025none ahead
Primus Pharmaceuticalsits history only10 open or runningphase 4since Apr 13, 2016Apr 13, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Sep 15, 2005.

  1. Oct 21, 2005Phase 3 study in Psoriasis of ScalpNCT00243464 · 300 enrolled · Belgium, Canada, Denmark and more
  2. Nov 3, 2005Phase 4 study in Psoriasis VulgarisNCT00248456 · 320 enrolled · China
  3. Dec 8, 2005Phase 2 study in Psoriasis VulgarisNCT00263718 · 360 enrolled · Canada, Germany, Ireland and more
  4. Jan 5, 2009Phase 2 study in Psoriasis VulgarisNCT00817219 · 33 enrolled · United States
  5. Apr 2, 2009Phase 2 study in Psoriasis VulgarisNCT00875277 · 24 enrolled · France
  6. Feb 16, 20122 phase 2 studies in Psoriasis VulgarisNCT01536938, NCT01536886
  7. May 8, 2012Phase 2 study in Psoriasis VulgarisNCT01600222 · 37 enrolled · Canada
  8. May 28, 2013Phase 3 study in Psoriasis VulgarisNCT01866163 · 426 enrolled · United States
  9. Aug 27, 2013Phase 1 study in Psoriasis VulgarisNCT01935869 · 224 enrolled · France
  10. Jan 27, 2015Phase 1 study in Skin and Connective Tissue DiseasesNCT02355639 · 16 enrolled · Germany
  11. Feb 25, 2015Phase 1 study in Dermatitis, AtopicNCT02376049 · 30 enrolled · Canada, Israel
  12. Mar 12, 2015Phase 2 study in Psoriasis VulgarisNCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
  13. Nov 22, 2016Phase 1 study in Psoriasis VulgarisNCT02973776 · 36 enrolled · France
  14. Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisNCT05919082 · 604 enrolled · China

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

All 18 LEO Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05919082Stable Plaque Psoriasis · China3CompletedFeb 23, 2024604
NCT02973776Psoriasis Vulgaris · France1CompletedFeb 201736
NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more2CompletedMar 28, 2018117
NCT02376049Dermatitis, Atopic · Canada, Israel1CompletedJul 201530
NCT02355639Skin and Connective Tissue Diseases · Germany1CompletedApr 201516
NCT01935869Psoriasis Vulgaris · France1CompletedNov 2013224
NCT01866163Psoriasis Vulgaris · United States3CompletedOct 2013426
NCT01600222Psoriasis Vulgaris · Canada2CompletedMay 201337
NCT01536938Psoriasis Vulgaris · United States2CompletedSep 2012303
NCT01536886Psoriasis Vulgaris · United States2CompletedSep 2012376
NCT00875277Psoriasis Vulgaris · France2CompletedMay 200924
NCT00817219Psoriasis Vulgaris · United States2CompletedDec 201133
NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more2Completed360
NCT00248456Psoriasis Vulgaris · China4Completed320
NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more3Completed300
NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more3Completed800
NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more3Completed1,350
NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more3Completed1,485

How it is read

Names in the registry

  • “LEO 90100”, 7 entries
  • “MC2-01 cream”, 4 entries
  • “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
  • “MC2-01 Cream”, 2 entries
  • “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.